menu
    • menu
    [{"orgOrder":0,"company":"ProLynx","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ National Cancer Institute"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"Intezyne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Intezyne","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intezyne \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intezyne \/ Undisclosed"},{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Nippon Kayaku","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nippon Kayaku \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nippon Kayaku \/ Undisclosed"},{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Nippon Kayaku","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nippon Kayaku \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nippon Kayaku \/ Undisclosed"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Locnartecan","moa":"||HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tarveda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for 7-Ethyl-10-Hydroxycamptothecin

    Menu

    7-Ethyl-10-Hydroxycamptothecin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ProLynx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx Initiates Phase II of PLX038 in Triple-Negative Breast Cancer at Institut Curie

                            Details : PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38. It is being evaluated for the treatment of locally-advanced or metastatic triple-negative breast cancer.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ProLynx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx Initiates Phase I/II of PLX038 in Rare CNS Tumors at National Cancer Institute

                            Details : PLX038 is a long-acting prodrug of the topoisomerase 1 inhibitor, It is being evaluated in phase 1/2 clinical trials for the treatment of primary CNS tumors driven by MYC or MYCN amplifications.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 05, 2024

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ProLynx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx Announces Initiation Of Phase II Clinical Trial Of Its DNA-Damaging Agent PLX038 in Patients With Plat...

                            Details : PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of D...

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            October 07, 2022

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tarveda Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Tarveda Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Locnartecan,7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tarveda Therapeutics to Present Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meet...

                            Details : PEN-866, a miniature drug conjugate composed of 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through heat shock protein 90 (Hsp90) for treatment of solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 21, 2020

                            Lead Product(s) : Locnartecan,7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ProLynx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin,Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38)

                            Details : PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of D...

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 13, 2020

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin,Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Intezyne

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Intezyne

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer

                            Details : IT-141 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 30, 2017

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nippon Kayaku

                            Japan arrow
                            OTS 2025
                            Not Confirmed

                            Nippon Kayaku

                            Japan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer

                            Details : NK012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 11, 2010

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nippon Kayaku

                            Japan arrow
                            OTS 2025
                            Not Confirmed

                            Nippon Kayaku

                            Japan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

                            Details : NK012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 11, 2010

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth